Erratum: Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not available (Bone Marrow Transplantation (2015) 50 (865-867) DOI: 10.1038/bmt.2015.22);Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not available

Bone Marrow Transplantation

Volumn 50, Issue 6, 2015, Pages 865-867

  Garciaz, S ^a   Castagna, L ^b   Bouabdallah, R ^a   Furst S ^a   Bramanti, S ^b   Coso, D ^a   Crocchiolo, R ^b   El Cheikh, J ^a   Broussais, F ^a   Chabannon, C ^a   Santoro, A ^b   Blaise, D ^a  

^a INSTITUT PAOLI CALMETTES   (France)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMOXICILLIN; BUSULFAN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FILGRASTIM; FLUCONAZOLE; FLUDARABINE; MYCOPHENOLATE MOFETIL; THYMOCYTE ANTIBODY; VALACICLOVIR;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ADVANCED CANCER; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; BK VIRUS; CANCER RECURRENCE; CHEMOPROPHYLAXIS; CHRONIC GRAFT VERSUS HOST DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DEATH; DONOR; FEMALE; FOLLICULAR LYMPHOMA; GRAFT VERSUS HOST REACTION; HEMORRHAGIC CYSTITIS; HERPES SIMPLEX; HUMAN; LARGE CELL LYMPHOMA; LETTER; LUNG ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MATCHED RELATED DONOR; MYCOSIS; NONHODGKIN LYMPHOMA; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; UNRELATED DONORS; WHOLE BODY RADIATION; ALLOGRAFT; DONOR SELECTION; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; PROCEDURES; STEM CELL TRANSPLANTATION;

ADULT; AGED; ALLOGRAFTS; DONOR SELECTION; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; STEM CELL TRANSPLANTATION; UNRELATED DONORS;

EID: 84930378927     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2015.79     Document Type: Erratum

References (15)

1. McClune BL, Ahn KW, Wang HL, Antin JH, Artz AS, Cahn JY, et al. Allotransplantation for patients age 4/= 40 years with non-Hodgkin lymphoma: encouraging progression-free survival. Biol Blood Marrow Transplant 2014; 20: 960-968
2. Rezvani AR, Storer B, Maris M, Sorror ML, Agura E, Maziarz RT, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol 2008; 26: 211-217
3. Sirvent A, Dhedin N, Michallet M, Mounier N, Faucher C, Yakoub-Agha I, et al. Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Biol Blood Marrow Transplant 2010; 16: 78-85
4. Kasamon YL, Luznik L, Leffell MS, Kowalski J, Tsai HL, Bolanos-Meade J, et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with highdose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant 2010; 16: 482-489
5. Luznik L, Jones RJ, Fuchs EJ. High-dose cyclophosphamide for graft-versus-host disease prevention. Curr Opin Hematol 2010; 17: 493-499
6. Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLAhaploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641-650
7. O'Donnell PV, Luznik L, Jones RJ, Vogelsang GB, Leffell MS, Phelps M, et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2002; 8: 377-386
8. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-956
9. Devillier R, Crocchiolo R, Castagna L, Furst S, El CJ, Faucher C, et al. The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT. Bone Marrow Transplant 2012; 47: 639-645
10. Luznik L, O'Donnell PV, Fuchs EJ. Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol 2012; 39: 683-693
11. Patriarca F, Luznik L, Medeot M, Zecca M, Bacigalupo A, Di BP, et al. Experts' considerations on HLA-haploidentical stem cell transplantation. Eur J Haematol 2014; 93: 187-197
12. Raiola AM, Dominietto A, di GC, Lamparelli T, Gualandi F, Ibatici A, et al. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts. Biol Blood Marrow Transplant 2014; 20: 1573-1579
13. Kanakry CG, O'Donnell PV, Furlong T, de Lima MJ, Wei W, Medeot M, et al. Multi-institutional study of post-transplantation cyclophosphamide as singleagent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol 2014; 32: 3497-3505
14. Pasquini MC, Devine S, Mendizabal A, Baden LR, Wingard JR, Lazarus HM, et al. Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation. J Clin Oncol 2012; 30: 3194-3201
15. Kanakry JA, Kasamon YL, Gocke CD, Tsai HL, Davis-Sproul J, Ghosh N, et al. Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. Biol Blood Marrow Transplant 2013; 19: 602-606